These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38329392)

  • 1. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry.
    Sanz-Garcia E; Brown S; Lavery JA; Weiss J; Fuchs HE; Newcomb A; Postle A; Warner JL; LeNoue-Newton ML; Sweeney SM; Pillai S; Yu C; Nichols C; Mastrogiacomo B; Kundra R; Schultz N; Kehl KL; Riely GJ; Schrag D; Govindarajan A; Panageas KS; Bedard PL
    Cancer Res Commun; 2024 Feb; 4(2):475-486. PubMed ID: 38329392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
    Choudhury NJ; Lavery JA; Brown S; de Bruijn I; Jee J; Tran TN; Rizvi H; Arbour KC; Whiting K; Shen R; Hellmann M; Bedard PL; Yu C; Leighl N; LeNoue-Newton M; Micheel C; Warner JL; Ginsberg MS; Plodkowski A; Girshman J; Sawan P; Pillai S; Sweeney SM; Kehl KL; Panageas KS; Schultz N; Schrag D; Riely GJ;
    Clin Cancer Res; 2023 Sep; 29(17):3418-3428. PubMed ID: 37223888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC) and Other Real-World Databases.
    Liu X; Alipour GH; Shao C; Burcu M; Bortnichak E; Vo T; Yu CL
    Pharmacoepidemiol Drug Saf; 2024 Aug; 33(8):e5851. PubMed ID: 39090803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for appendiceal and colorectal peritoneal metastases.
    Enblad M; Graf W; Birgisson H
    Eur J Surg Oncol; 2018 Jul; 44(7):997-1005. PubMed ID: 29576463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
    Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
    Papamichael D; Lopes GS; Olswold CL; Douillard JY; Adams RA; Maughan TS; Van Cutsem E; Venook AP; Lenz HJ; Heinemann V; Kaplan R; Bokemeyer C; Chibaudel B; Grothey A; Yoshino T; Zalcberg J; De Gramont A; Shi Q
    Eur J Cancer; 2022 Mar; 163():1-15. PubMed ID: 35033994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer.
    de Boer NL; Rovers K; Burger JWA; Madsen EVE; Brandt-Kerkhof ARM; Kok NFM; de Wilt JHW; de Reuver PH; Bos A; de Hingh IHJT; Verhoef C
    Cancer Med; 2020 Aug; 9(16):5851-5859. PubMed ID: 32614506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery.
    Peerenboom R; Dhiman A; Witmer HDD; Spurr LF; Polite B; Eng OS; Shergill A; Turaga KK
    Ann Surg Oncol; 2023 May; 30(5):3114-3122. PubMed ID: 36637640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
    Marques RP; Godinho AR; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2020 May; 146(5):1321-1334. PubMed ID: 32144533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
    Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
    Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer.
    Wang CY; Shao C; McDonald AC; Amonkar MM; Zhou W; Bortnichak EA; Liu X
    JCO Clin Cancer Inform; 2023 Jul; 7():e2200184. PubMed ID: 37437227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
    Sahin S; Karatas F
    J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AACR Project GENIE Biopharma Collaborative Releases Colorectal Cancer Dataset.
    Cancer Discov; 2023 Jan; 13(1):OF6. PubMed ID: 36355341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.
    Stein MK; Williard FW; Xiu J; Tsao MW; Martin MG; Deschner BW; Dickson PV; Glazer ES; Yakoub D; Shibata D; Grothey AF; Philip PA; Hwang JJ; Shields AF; Marshall JL; Korn WM; Lenz HJ; Deneve JL
    J Surg Oncol; 2020 Jun; 121(8):1320-1328. PubMed ID: 32166754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.